Yu Fujiwara

853 total citations · 1 hit paper
57 papers, 535 citations indexed

About

Yu Fujiwara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yu Fujiwara has authored 57 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Yu Fujiwara's work include Cancer Immunotherapy and Biomarkers (21 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer, Stress, Anesthesia, and Immune Response (6 papers). Yu Fujiwara is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer, Stress, Anesthesia, and Immune Response (6 papers). Yu Fujiwara collaborates with scholars based in United States, Japan and United Kingdom. Yu Fujiwara's co-authors include Shumei Kato, Razelle Kurzrock, Mary Nesline, Jeffrey M. Conroy, Sarabjot Pabla, Paul DePietro, Abdul Rafeh Naqash, Nobuyuki Horita, Arjun Mittra and Naoko Takebe and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Yu Fujiwara

50 papers receiving 522 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy

2022 195 citations Yu Fujiwara, Shumei Kato et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Fujiwara United States	13	300	141	106	99	72	57	535
Florent Peyraud France	11	279 0.9×	168 1.2×	119 1.1×	174 1.8×	50 0.7×	24	508
Avinoam Nevler United States	14	234 0.8×	39 0.3×	87 0.8×	239 2.4×	250 3.5×	74	673
Chuanyu Sun China	12	158 0.5×	34 0.2×	117 1.1×	109 1.1×	190 2.6×	27	444
Yingjie Shao China	9	200 0.7×	45 0.3×	104 1.0×	202 2.0×	105 1.5×	12	492
Sara Junius Belgium	6	233 0.8×	94 0.7×	144 1.4×	109 1.1×	34 0.5×	8	475
Rosekeila Simões Nomelini Brazil	14	235 0.8×	183 1.3×	26 0.2×	95 1.0×	77 1.1×	67	653
Yushen Wu China	14	213 0.7×	72 0.5×	114 1.1×	215 2.2×	92 1.3×	25	532
Yasuhiko Ohshio Japan	12	162 0.5×	109 0.8×	69 0.7×	98 1.0×	51 0.7×	32	375
Violeta Régnier Galvão Brazil	14	182 0.6×	257 1.8×	53 0.5×	72 0.7×	21 0.3×	22	729

Countries citing papers authored by Yu Fujiwara

Since Specialization

Citations

This map shows the geographic impact of Yu Fujiwara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Fujiwara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Fujiwara more than expected).

Fields of papers citing papers by Yu Fujiwara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Fujiwara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Fujiwara. The network helps show where Yu Fujiwara may publish in the future.

Co-authorship network of co-authors of Yu Fujiwara

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Fujiwara. A scholar is included among the top collaborators of Yu Fujiwara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Fujiwara. Yu Fujiwara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujiwara, Yu, Shingo Tamaki, Fuminobu Sato, & Isao Murata. (2025). Development of a New Low-Energy Neutron Spectrometer Using a Position-Sensitive Proportional Counter: Examination of the Response Function Considering the Spectrometer Shield. Journal of Radiation Protection and Research. 50(s1). S43–S48. 1 indexed citations

Salgia, Nicholas, Yu Fujiwara, Bo Xu, et al.. (2025). Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid Component. European Urology Focus. 11(3). 421–424.

Horita, Nobuyuki, et al.. (2024). Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials. Therapeutic Advances in Medical Oncology. 16. 12702610–12702610. 2 indexed citations

Moraes, Francisco Cézar Aquino de, Ludimila Cavalcante, Yu Fujiwara, et al.. (2024). Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.. Journal of Clinical Oncology. 42(16_suppl). 8642–8642. 2 indexed citations

Horita, Nobuyuki, et al.. (2024). Association between the occurrence of immune-related adverse events and survival outcomes in patients with cancer treated with perioperative immune checkpoint inhibitors: A systematic review and meta-analysis.. Journal of Clinical Oncology. 42(23_suppl). 39–39. 1 indexed citations

Fujiwara, Yu, et al.. (2024). Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial Eligibility. JAMA Network Open. 7(9). e2433387–e2433387.

Fujiwara, Yu, Francisco Cézar Aquino de Moraes, Natasha B. Leighl, et al.. (2024). Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO Precision Oncology. 8(8). e2400331–e2400331. 4 indexed citations

Fujiwara, Yu, et al.. (2024). Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis. Cancer Treatment Reviews. 131. 102833–102833. 8 indexed citations

Fujiwara, Yu, et al.. (2024). C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 197. 104352–104352. 8 indexed citations

10.

Agarwal, Siddharth, Yu Fujiwara, Avirup Guha, et al.. (2024). The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Patients With Cancer: A Systematic Review and Meta-Analysis. The American Journal of Cardiology. 216. 87–90. 6 indexed citations

11.

Fujiwara, Yu, Yasuyoshi Sato, Naomi Hayashi, et al.. (2023). The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin. Journal of Geriatric Oncology. 14(5). 101523–101523. 5 indexed citations

12.

Fujiwara, Yu, Nobuyuki Horita, Elio Adib, et al.. (2023). Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. The Lancet Oncology. 25(1). 62–75. 26 indexed citations

13.

Kato, Shumei, Yu Fujiwara, & David S. Hong. (2022). Targeting KRAS : Crossroads of Signaling and Immune Inhibition. SHILAP Revista de lepidopterología. 5(3). 68–78. 9 indexed citations

14.

Ohmoto, Akihiro, Yu Fujiwara, Nobuyuki Horita, Kenji Nakano, & Shunji Takahashi. (2022). Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discover Oncology. 13(1). 3 indexed citations

15.

Horita, Nobuyuki, Ho Namkoong, Yu Fujiwara, et al.. (2022). Adverse events induced by nivolumab and ipilimumab combination regimens. Therapeutic Advances in Medical Oncology. 14. 4277470425–4277470425. 14 indexed citations

16.

Sato, Yasuyoshi, Naoki Fukuda, Yu Fujiwara, et al.. (2021). Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. In Vivo. 35(2). 1211–1215. 14 indexed citations

17.

Fukuda, Naoki, Mayu Yunokawa, Yu Fujiwara, et al.. (2020). Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer Reports. 4(2). e1322–e1322. 7 indexed citations

18.

Fujiwara, Yu, Takeshi Yamaguchi, & Minoru Nakane. (2020). Granulocyte Colony-Stimulating Factor–Associated Aortitis: Treatment Suggestion for This Complication. JCO Oncology Practice. 17(1). 57–58. 12 indexed citations

19.

Fujiwara, Yu, et al.. (2019). Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP. Urology Case Reports. 24. 100883–100883. 2 indexed citations

20.

Mitsutake, Seigo, Mariko Nishi, Erika Kobayashi, et al.. (2018). THE ASSOCIATIONS OF SOCIAL ISOLATION WITH MEDICAL AND LONG-TERM CARE UTILIZATION AMONG OLDER ADULTS IN JAPAN.. Innovation in Aging. 2. 1017–1017. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact